Skip to content
Home/Companies/Biotech/Odyssey Therapeutics

Odyssey Therapeutics

Biotech·France·Exited 2026·Held 1yr
Entry
2025
Hold
1yr
Exit
2026

Who owns Odyssey Therapeutics?

Odyssey Therapeutics is a French Biotech company, formerly owned by Jeito Capital, exited in 2026 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito II · 2026 · VC

Key facts

HQFrance
SectorBiotech
Exit Type
IPO
Exit Year
2026

More from Jeito II

Other portfolio companies in the same fund.

Adcendo
Adcendo
Active
BiotechDenmark· 2026
Alveus Therapeutics
Alveus Therapeutics
Active
BiotechUS· 2026
Bionyra Pharma
Active
BiotechFrance· 2026
Augustine Therapeutics
Augustine Therapeutics
Active
BiotechBelgium· 2025
Azafaros
Azafaros
Active
BiotechNetherlands· 2025
Callio Therapeutics
Active
BiotechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Odyssey Therapeutics?

Odyssey Therapeutics was formerly owned by Jeito Capital, exited in 2026. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue